Kairos Pharma, Ltd. (KAPA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 57/100 (HIGH), 9.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.92% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
- Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
- Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Kairos Pharma Announces 1-for-7 Reverse Stock Split
- Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
- CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever
- Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
- Bayer (XTRA:BAYN) Stock Still Looks Reasonable On New Prostate Cancer News
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Kairos Pharma, Ltd..
Full KAPA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.